Dr Enriqueta Felip (Vall d'Hebron University Hospital, Barcelona, Spain), Dr Alex Spira (Virginia Cancer Specialists Research Institute, Fairfax, USA), Dr Antonio Passaro (European Institute of Oncology, Milan, Italy) and Dr Alfredo Addeo (University Hospital of Geneva, Geneva, Switzerland) discuss the advances in NSCLC at ASCO 2024.

The panel talks about the data from the PALOMA 2 and 3 trials on the subcutaneous delivery of drugs. They then provide updates on the MARIPOSA and CHRYSALIS trials.

The panel also talks about HARMONi-A, WU-KONG1 and LAURA studies.